Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study
SHINE-1 Results Suggest EB-001A May Improve Appearance of ScarsBonti, a privately-held, clinical-stage biotechnology company, today announced the topline results of its SHINE-1 Phase 2a clinical trial, the first clinical trial in its SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction. SHINE-1 evaluated EB-001A, Bonti’s aesthetic product candidate, for scar reduction